The next generation of RAGE modulators: implications for soluble RAGE therapies in vascular inflammation

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis

(2013) Brendan M. Everett et al.   AMERICAN HEART JOURNAL

The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth

(2013) Hyun-Jin Tae et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Alarmins: awaiting a clinical response

(2012) James K. Chan et al.   JOURNAL OF CLINICAL INVESTIGATION

S100A12 Expression in Thoracic Aortic Aneurysm Is Associated With Increased Risk of Dissection and Perioperative Complications

(2012) Deepanjana Das et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

S100A12 in Vascular Smooth Muscle Accelerates Vascular Calcification in Apolipoprotein E–Null Mice by Activating an Osteogenic Gene Regulatory Program

(2010) Marion A. Hofmann Bowman et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The RAGE Axis

(2010) Shi Fang Yan et al.   CIRCULATION RESEARCH

Carboxylated N-glycans on RAGE promote S100A12 binding and signaling

(2010) Geetha Srikrishna et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE–/– mice

(2008) Evis Harja et al.   JOURNAL OF CLINICAL INVESTIGATION